Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2023 Financial Results
Initial clinical results from Phase 2 SUMMIT trial in NonAdvSM along with updated data from Phase 2 APEX trial in...
Year: 2023
Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Malignant Glioma
BASKING RIDGE, N.J., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage...
Ocuphire Pharma to Present at the Canaccord 43rd Annual Growth Conference and the H.C. Wainwright Ophthalmology Conference in August
FARMINGTON HILLS, Mich., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused...
Theriva™ Biologics Reports Second Quarter 2023 Operational Highlights and Financial Results
- Initiated dosing at U.S. sites for VIRAGE, the Phase 2b clinical trial of VCN-01 in combination with chemotherapy for...
Grace Breeding’s Environmentally Friendly WDS Climate Stress Tolerance Solution Receives its First European Product Registration in Germany
- Grace Breeding’s WDS, a proprietary and environmentally friendly formula to counteract crop climate stress, will be marketed under the...
Cocrystal Pharma Selects Novel Oral Protease Inhibitor CDI-988 as Norovirus Lead
First dual coronavirus-norovirus oral antiviral is scheduled for Phase 1 in healthy volunteers In vitro studies show broad-spectrum activity against...
DLH to Participate in Upcoming Sidoti Micro Cap Conference
ATLANTA, Aug. 08, 2023 (GLOBE NEWSWIRE) -- DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading healthcare and...
Mersana Therapeutics Announces Second Quarter 2023 Financial Results
Organization fully focused on product candidates and collaborations based on next-generation ADC platformsCapital resources expected to support current operating plan...
Recursion Provides Business Updates and Reports Second Quarter 2023 Financial Results
Recursion's Pipeline Recursion's internal pipeline as of Q2 2023Deployed new digital chemistry technology, together with NVIDIA, to predict the ligand-protein...
Tecan schedules conference call on August 15th to discuss half year 2023 financial results
Männedorf, Switzerland, August 8, 2023 – The Tecan Group AG (SIX Swiss Exchange: TECN) will hold a conference call to...
CorMedix Inc. Reports Second Quarter and Six Month 2023 Financial Results and Provides Business Update
Conference Call Scheduled for Today at 8:30 a.m. Eastern TimeBERKELEY HEIGHTS, N.J., Aug. 08, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc....
Abeona Therapeutics Reports Second Quarter 2023 Financial Results
On track for Biologics License Application (BLA) submission in third quarter of 2023 Proceeds from $25 million registered direct offering...
Neuronetics Reports Record Second Quarter 2023 Financial and Operating Results
MALVERN, Pa., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”) a commercial stage medical technology...
XOMA Reports Second Quarter 2023 Financial Results and Provides Update on its Royalty Monetization Strategy
Completed two royalty acquisitions in the first half of 2023 adding one cash flow generating asset, one NDA-ready asset, and...
Bioventus Reports Second Quarter Financial Results; Introduces Full Year 2023 Financial Guidance
DURHAM, N.C., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in...
Cronos Group Reports 2023 Second Quarter Results
Industry-leading balance sheet with $841 million in cash and short-term investments Increased 2023 operating expense savings target to $20 to...
Freeline Therapeutics to Host Second Quarter 2023 Financial Results Call
LONDON, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that it will host a...
Verrica Pharmaceuticals Reports Second Quarter 2023 Financial Results
– In July, FDA approved YCANTH™ for the treatment of molluscum, a highly contagious viral skin infection affecting approximately 6...
Anavex Life Sciences Reports Fiscal 2023 Third Quarter Financial Results
On track to release top-line data of potentially pivotal ANAVEX®2-73-RS-003 Phase 2/3 EXCELLENCE pediatric clinical trial in the second half...
Harvard Bioscience Announces Second Quarter 2023 Financial Results
Q2 Revenues of $28.8 millionQ2 GAAP operating income $0.8 million, adjusted operating income $3.6 millionStrong H1 operating cash flow drove...